(RTTNews) – Spyre Therapeutics, Inc. (SYRE), a clinical-stage biotech firm centered on modern antibody therapies for Inflammatory Bowel Illness or IBD and associated immune issues, Monday introduced two poster shows at Digestive Illness Week or DDW 2025, held from Might 3-6 in San Diego, California.

The corporate offered eight-month follow-up information from its Section 1 trial of SPY001, a half-life prolonged a4ß7 antibody. The up to date outcomes present SPY001 continues to be nicely tolerated, has a half-life greater than 3 times longer than vedolizumab based mostly on pharmacokinetic (PK) modeling, and maintains sustained goal engagement at anticipated Section 2 trough ranges. This helps its potential for enhanced induction and long-lasting responses, with upkeep dosing probably solely wanted quarterly or twice a 12 months.

Preclinical information additionally demonstrated that twin inhibition of a4ß7 integrin and TL1A cytokine gives superior efficacy over particular person therapies in mouse fashions of colitis. No drug-drug interactions had been noticed in non-human primates co-administered SPY001 and SPY002.

Dr. Deanna Nguyen, SVP of Scientific Improvement at Spyre, famous that the prolonged follow-up information reinforce the potential for SPY001 to supply best-in-class quarterly or biannual dosing for IBD sufferers. She added that Spyre plans to guage SPY001 each as a standalone remedy and as a mix spine in its upcoming Section 2 platform trial in ulcerative colitis, which is scheduled to launch mid-2025.

Each posters can be found throughout the DDW 2025 exhibition. Full session particulars will be discovered within the official DDW program.

SYRE is presently buying and selling at $13.97 or 7.58% decrease on the Nasdaq International Choose Market.

The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.